Transcripta Bio discloses $24M raised since Series A for clinical prep

Chris Moxham is moving autism and FSHD programs toward the clinic, though the financing has no disclosed lead, valuation or single close date.

By · Published

Primary source: Business Wire

Why it matters

Mayo Clinic's financial interest gives Moxham an institutional backer as Transcripta Bio enters the costliest test of AI drug discovery: turning predictions into clinical evidence.

The intricate machinery of drug discovery, visualized at a molecular and cellular level (Exploded-view technical diagram, rendered with fine, crisp lines and isolated, labeled parts, reminiscent of a modern scientific illustration manual)

Chris Moxham, the veteran drug hunter running Transcripta Bio, has added Mayo Clinic and healthcare investor Omnimed to $24 million of financing raised since Transcripta Bio's Series A, Transcripta Bio said in a Business Wire announcement on July 22nd.…

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.